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Background: During these moments of anxiety, fear and to some extent 
despair, it is imperative for everyone to have access to the right information. 
This can be achieved through breaking down the science and medical 
terminologies used to express the scenarios emanating from the COVID-19 
pandemic. Forward: This commentary focuses on the most asked 
questions that, when not answered with scientific grounds to convince the 
non-medics can result in non-science based “infodemics”. The brief history 
behind COVID-19 pandemic, the science of SARS-CoV-2, the taxonomies 
used, a brief on the Pathophysiology of SARS-CoV-2, the genetic make up, 
most vulnerable indivduals, antibodies against COVID-19, mother to baby 
transmission, conspiracy theories reagading the virus being weaponized, 
mutations occurring with SARS-CoV-2 and reoccurrence of COVID-19 
in the future are all explained at great length. The review made references 
to the existing  publications  regarding this pandemic. Conclusion: While 
the science regarding this virus is not exhausted, we confirmed that, the 
knowledge gap between non-medics and medics is wide. The results 
emerging from the pandemic to form data are questionable, so it is our 
collective responsibility to fight against this virus in order to stop further 
spreading by providing the right information to the public. If we would not 
come together to fight and win this battle, we might be witnessing many 
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1. Introduction 
January 9th, 2020, the Chinese Center for Disease Control and Prevention (CDC) formally confirmed to the Wall Street Journal that, a novel coronavirus 
(CoVs) previously unknown to science has been reported 
to be responsible for an outbreak of respiratory illnesses. 
This emerging public health concern at the time will later 
be responsible for the first coronavirus pandemic[1,2]. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
that causes coronavirus disease 2019 (COVID-19) is 
responsible for the current pandemic, which is affecting 
lives in various ways. The virus was first isolated in 
patients seen in Hubei province, Wuhan, China who were 
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found to have pneumonia. The cluster of pneumonia 
cases were seen in patients who were suspected to 
have links to a seafood market. This lead to the closure 
and decontamination by the Chinese officials[3]. The 
World Health Organization (WHO) officially declared 
COVID-19 epidemic as a public health emergency 
of international concern (PHEIC) on Janury 30 th and 
passengers with travel links to Wuhan are being subjected 
to screening[4]. A group of Chinese scientists on the 7th 
of January 2020, rapidly isolated the SARS-CoV-2 a 
β-coronavirus from a patient within a short time frame 
and subsequently genome sequencing was done for the 
global scientific community to join the science behind the 
new enemy of humanity[5].
This devastating pandemic has called for an urgent 
and highly professional containment measures to limit 
physical, mental and socio-economic problems. The 
expertise ranges from emergency response which includes, 
case detection, quarantine and isolation to the need for a 
more extensive evaluation of diagnostic capacities and 
preparedness, in anticipation of any disease epidemic[6,7]. 
Despite the previous outbreaks and the fatal outcomes 
associated with, evidence gathered from the media has it 
that, people around the world are seemingly not taking 
this pandemic gravely. More than 1 million of people 
lost their lives to this enemy already and more lives are 
claimed daily due to complications caused by the disease. 
Economies and different sectors, which are essential for 
basic living are also impacted hugely. Therefore, it is 
crucial to break the medical information to non-medical 
personnel. This will enhance adequate measures to prevent 
further damages to lives. Suffice it to say that, the need to 
shed more light on the fundamentals of this disease and 
to dispel the many conspiracy theories associated with 
the pandemic to the non-medical personnel will go a long 
way in saving many precious lives and also have a minor 
impact on the socio-econimic activities of the world. 
2. History of SARS-CoV-2 Pandemic 
On the 12th December 2019, initial cases of COVID-19 
were discovered in Wuhan, a province in China. 
However, the origins of the pandemic of the unknown 
acute respiratory tract infection has no scientific proof as 
speculations related it to the seafood market in Wuhan. 
Despite the studies whose conclusions stood as the 
potential reservoir of SARS-CoV-2, until today there is 
no scientific evidence that, the virus is contracted from 
the seafood market [8]. In addition, based on the virus’s 
genome sequencing that gave 96.2% overall genome 
sequence similarity between this novel virus and Bat 
CoV RaTG13, thus making it fit to share same possible 
ancestors. It is important to note that, bats are not found 
in this seafood market in Wuhan. Furthermore, protein 
sequence alignment and phylogenetic analysis proved 
possible alternative intermediate hosts, such as pangolins, 
snakes and turtles. This is based on the similarities of 
receptors that are observed in many of these species [9]. 
3. Novel SARS-CoV-2 Virus
To many, the SARS-CoV-2 causing COVID-19 is totally 
a new virus. However, this is just the newest form 
emerging from the coronavirus (CoVs) family and the first 
coronavirus to be responsible for a global pandemic. There 
are two other CoVs that emerged as novel coronavirus, 
causing epidemics and claimed lives previously. SARS-
CoV, which emerged in china killed 916 out of 8422 
confirmed cases (10.87%) and spread across 32 countries. 
MERS-CoV infected 2496 and claimed 868 (34.77%) 
lives while crossing boundaries of 27 different countries. 
Prior to these two super-spreading viruses, coronaviruses 
were studied as having a low potential for community 
transmission. The big family of CoVs are divided into 
four genera alpha, beta, gamma and delta (α−/β−/γ−/
δ-CoV). The first two infect mammals including humans 
and the last two are found to infect birds. Prior to this 
novel β-SARS-CoV-2, six CoVs have been identified 
and apart from the β-CoVs, SARS-CoV and MERS-CoV 
that caused potentially fatal respiratory tract infections, 
low pathogenicity induced CoVs strains that caused mild 
symptoms, very similar to common cold were identified. 
If interest will rise on studying coranviruses, these are 
α-CoVs HCoV-229E and HCoV-NL63, and β-CoVs 
HCoV-HKU1 and HCoV-OC43 [10].
The newest member of the family, that is devastating 
the world, started at the end of 2019 through 2020 and 
now has gained a pandemic status. This is affecting daily 
activities of living and causing socio-economic crises 
while claiming lives of many is called severe acute 
respiratory syndrome virus 2 or SARS-CoV-2 and it was 
first discovered in a city called Wuhan in central China. 
The outbreak occurred exactly when the world’s largest 
migration (Chinese lunar new year spring festival) was 
happening. Meaning extreme high air and train traffics 
came along with the virus [11]. That is the reason behind 
its rapid spread across the globe and despite low fatality 
compared to diseases caused by both SARS-CoV and 
MERS-CoV. As of April 21st according to worldometer, 
the virus had claimed the lives of 170,439 and infected 
2,481,528 globally. While the recovery rate is 79% and 
the death rate is 21% making a case fatality rate of 0.069%. 
It is important to note that, these figures might not directly 
represent the true picture of the fatality of the virus as 
DOI: https://doi.org/10.30564/jor.v2i2.2447
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the data is only based on cases that received an official 
diagnosis. Some of the asymptomatic cases would never 
present to a health care facility for diagnosis, therefore 
they will not be part of the statistics.
The scientific evidences have gathered that this 
novel coronavirus is more contagious compared to 
its other family members. In addition, it has diverse 
epidemiological and biological characteristics, which 
makes it possible to infect many people in a short 
duration of time[11]. The virus is enveloped non-segmented 
positive-sense RNA virus (subgenus sarbecovirus, 
Orthocoronavirinae subfamily). 
4. The Taxonomy of SARS-CoV-2 and 
COVID-19
On the 11th February, 2020 WHO officially named the 
disease caused by this novel virus as coronavirus disease 
2019 (COVID-19). The virus is named as Severe acute 
respiratory syndrome virus 2 or SARS-CoV-2 by the 
Coronavirus Study Group (CSG) of the International 
Committee on Taxonomy of Viruses (ICTV) due to its 
89% nucleotide identity with bat SARS-like-CoVZXC21 
and 82% with that of human SARS-CoV [11]. The word 
coronam is the Latin term for crown, due to the presence 
of spike glycoproteins on the envelope in the subfamily 
Orthocoronavirinae of the Coronaviridae family (order 
Nidovirales). According to WHO, it is important to name 
diseases to enable discussions on prevention, spread and 
transmissibility, severity and treatment. And also these 
names were chosen to avoid stigmatizing the virus’s origin 
in terms of geography, populations or animal associations.
5. A Brief Summary on the Pathophysiology 
of SARS-CoV-2 
COVID-19 infect the body by holding onto receptors 
and entering healthy cells. Receptors are proteins on 
the surface or inside of cells which is able to recognize 
chemical substances, viruses and drugs for example). 
Once inside the cell, the virus makes copies of itself and 
multiplies throughout the cells in the body by making new 
proteins leading to formation of new viruses. The novel 
coronavirus uses the same receptor as that of the SARS-
CoV, and mainly spreads through the respiratory tract it 
can gain entry into the body through the eyes, nose, or 
mouth. It then enters the cells by using its spikey surface 
proteins to attach to receptors on normal cells, especially 
those in the airways. The angiotensin-converting enzyme 
2 (ACE2) found in abundance in the human’s lower 
respiratory tract, is known as the cell receptor for SARS-
CoV which causes SARS [12] and also regulates both cross-
species and human-to-human transmission [13]. 
This viral entry was reported, when they isolated 
COVID-19 from the bronchoalveolar lavage fluid, and 
they confirmed that the SARS-CoV-2 uses the same 
cellular entery mechanism (ACE2) as SARS-CoV [14].
The CoVs S protein mediates the entery of the virus into 
host cells [15], then receptor-binding domain (RBD) within 
the S1 domain facilitate binding to host cell receptor and 
S2 domain facilitate the viral fusion between host cell 
membrane and viral membrane which is an essential part 
in the entery of CoVs into host cells [16,17]. Once inside, 
the coronavirus hijacks the healthy cells and takes over 
command. Eventually, they kill some of the healthy 
cells and new viruses will infect other healthy cells and 
this goes on and on since it is in control of the genetic 
mechanism of the cells.
As the infection reaches the lower respiratory system, 
including the lungs, breathing becomes difficult. This 
is when more serious medical problems can develop, 
problems like pneumonia. This makes the airways swell 
and the lungs fill with fluid. In the most severe cases, 
this fluid in the lungs can lead to acute respiratory 
distress syndrome, or ARDS. People with ARDS are 
usually already hospitalized. ARDS makes it difficult 
or impossible to breathe because the lungs are grossly 
inflamed making gas exchange with the breathing in 
of oxygen and expulsion of carbondioxide as a waste 
product difficult leading to suffocation of tissues. As fluid 
collects in the lungs, they carry less oxygen to the blood. 
That means the blood may not supply organs with enough 
oxygen to survive. This can cause organs like the kidneys, 
lungs, and liver to fail and stop working leading to multi 
organ failure and eventually death [16].
However, it is important to mention that not everyone 
who gets infected with COVID-19 will develop serious 
complications needing hospital admission and advanced 
medical attention. Asymptomatic and mild cases may need 
supportive treatment at home or at an isolation center.
6. The Genetic Make Up of SARS-CoV-2
This virus is an enveloped positive single-stranded RNA 
(ssRNA) from the coronavirus family. The open reading 
frame (ORF 1a/b) encodes 16 non-structure protiens 
(NSPs) and two-thirds of the viral RNA mianly located in 
the (ORF 1a/b). The rest of the viral genome encodes for 
essential structural protein such as spike (S) glycoprotein, 
matrix (M) protein, nucleocapsid (N) protein, small 
envelope (E) protein and several accessory proteins [13]. 
The virulent factor that enables SARS-CoV-2 to binds to 
host cells receptor angiotensin-converting enzyme (ACE2) 
and enter in the host cells is S glycoprotein. Receptor-
DOI: https://doi.org/10.30564/jor.v2i2.2447
19
Journal of Oncology Research | Volume 02 | Issue 02 | July 2020
Distributed under creative commons license 4.0
binding domain (RBD); heptad repeat (HR) 1 and 2. What 
is yet to be clear until today, is the possible molecules 
facilitated membrane invagination for SARS-CoV-2 
endocytosis. Like many “self and nonself” mechanisms 
occurring, host factors (Lower panel) influences 
susceptibility to infection and disease progression [19].
7. People Most Vulnerable to SARS-CoV-2 
Risk factors for severe COVID-19 includes and is not 
limited to advanced age, immunocompromised state, 
diabetes, cardiovascular disease including hypertension, 
chronic pulmonary disease, chronickidney disease, liver 
disease, cancer and severe obesity [20]. Everyone is at 
risk but the groups mentioned with underlying health 
problems are at greater risk due to weak immune systems 
and dysfunctions in various organ systems of the body. 
Smoking, to date, has been assumed to be possibly 
associated with adverse disease prognosis, as extensive 
evidence has highlighted the negative impact of tobacco 
use on lung health and its causal association with a 
plethora of respiratory diseases [21]. Previous studies have 
shown that smokers are twice more likely than non-smokers 
to contract influenza and have more severe symptoms, 
while smokers were also noted to have higher mortality in 
the previous MERSCoV outbreak [22,23]. Smoking cigarettes 
increases viral receptors on the respiratory surface, which 
might explain the increase in deaths in smokers reported 
by early researches on the disease.
It is noteworthy that, infants and children have not been 
featured prominently in COVID-19 case statistics. Despite 
the global pandemic of COVID-19, the clinical patterns 
and epidemiological findings remain unclear, especially 
among these groups. According to reports on COVID-19 
among Chinese children in Wuhan, compared to adults, 
children were less likely to be infected and to have a 
severe illness, but they are still at risk from this pandemic. 
A nationwide study of 2143 COVID-19 pediatric patients 
conducted between January and February 2020 by the 
Chinese Center for Disease Control and Prevention, 
reported that all children of all ages were susceptible 
to COVID-19 without significant gender difference. 
Moreover, the severity of clinical manifestation among 
children infected with SARS-CoV-2 was generally less 
severe compared to adult patients and infants that were 
vulnerable to infection [24].
Another analysis from China also saw that, children 
younger than 10 years account for only 1% of COVID-19 
cases [25], similar to the proportion for SARS-CoV and 
MERS-CoV epidemics [26,27]. Infants and young children 
are typically at high risk for admission to hospital after 
respiratory tract infection with viruses such as respiratory 
syncytial virus and influenza virus. Immaturity of the 
respiratory tract and immune system is thought to 
contribute to severe viral respiratory disease in this age 
group [28]. Therefore, the absence of paediatric patients 
with COVID-19 has perplexed clinicians, epidemiologists, 
and scientists. Case definitions and management strategies 
for children are absent because of the limited number of 
paediatric patients with COVID-19.
Athough blood groups are not established biomarkers, 
based on existing studies, people with blood type A are 
at higher risk of infection compared to non-A blood 
groups while blood type O has a significant lower risk for 
infection and severity compared to non-O blood groups. 
Although the higher death rate are seen among elderly 
people and those with pre-existing health issues. A study 
conducted in Wuhan, China found that, those with type A 
blood group are more likely to die from COVID-19 [29].
8. Antibodies Against COVID-19
Based on the available scientific data, the evidence on 
COVID-19 induced immunity is limited. That is to say, 
whether any immunity would give long-lasting protection 
against the virus is yet to be clear. A woman in Japan was 
reported to have tested positive for the second time after been 
given all the clear and also in China SARS-CoV-2 positive 
men became positive for the second time [30]. Until we see 
different occurrences, it means that, there is possibility for 
reinfections and repeated rounds until there is a vaccine 
or a herd immunity is developed. Herd immunity is when 
50% of the population got sick and recovered while 
developing antibodies against the viral antigen [31]. Again 
since there is a knowledge gap surrounding the entire 
science of this virus, not everything said or speculated 
is uncertain. According to Ira Longini at the University 
of Florida, there is an evidence centered on anecdotal 
reinfection. But he added, that “we really don’t know”. 
A breakthrough was seen on mouse model study 
conducted by the Chinese Academy of Medical Sciences 
in Beijing after exposing four rhesus macaques to the 
virus, they came up with the conclusion that, mice have 
antibodies to the virus in their bloodstream. And they 
tried to re-infect them but it fails, meaning the animals are 
immune. However, this might not necessary be a long-
term induce imunity. For example, some people develop 
common cold immunity but this induced immunity are 
most often relatively short-lived. On the contrary to this as 
per humans, researchers at the London School of Hygiene 
& Tropical Medicine (LSHTM) reported that there is an 
increasing convincing evidence that, infection with SARS-
CoV-2 leads to an antibody response that is protective. 
Although they request more evidence, their stance is on 
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antibody protection for life. That means, there will be no 
second experience for infection. However, everything 
we are learning about this virus is new and independent 
researchers are required in order to understand how 
protective the antibody response will be in the long-
term. To sum of the issue of re-infecting, WHO warned 
against declaring recovered patients “risk free” since 
currently there is no evidence that people recovered from 
COVID-19 and have antibodies are protected from second 
infection. 
9. Mother to Baby Transmission 
According to the CDC, during pregnancy, the transmission 
of SARS-CoV to the fetus or the baby during delivery 
is still unknown. Although, no neonates born to positive 
mothers are seen to have COVID-19 or infected and tested 
positive for the virus. In such cases, which were a small 
number, the amniotic fluid or breastmilk was free of the 
virus [32]. Moreover, a very recent case report conducted by 
Chen Y, et al [33] described the clinical course of four live-
born infants. These infants were born to pregnant women 
infected with the COVID-19. Due to concerns about 
symptomatic maternal infection, three of the four women 
had a Cesarean (C) section and the for the fourth infant, 
his birth was through a vaginal delivery. None of the four 
newborns developed COVID-19 infection [33]. Another 
recent study conducted by Chen et al in February 2020 
in China, that involved nine pregnant women infected 
with SARS-CoV-2 and developed pneumonia. There 
was no reported evidence of verticle transmission of the 
virus from women infected with the novel coronavirus 
to their infants [34]. However, a new study conducted by 
Zeng et al [35] suggested that, vertical transmission of the 
virus from infected mother with COVID-19 to the fetus is 
possible.
10. Conspiracy on the Virus being Weaponized
Following the rumors that the virus might escaped from 
a high-security biochemical lab in Wuhan, China, experts 
used the e genome sequences made available by the 
Chinese to explore the origins of and evolution of SARS-
CoV-2. Apparently, from the studies done by scientists 
around the globe, they could not find any proof that the 
virus is made in a laboratory or engineered. This is based 
on the public genome sequence data from SARS-CoV-2 
and related viruses. The science behind is to analyze the 
genetic template for spike proteins, armatures on the 
outside of the virus that grabs and penetrate the outer 
walls of host cells. 
Until now, we could not established scientific grounds 
as to the virus being weaponized although the levels of 
genetic similarity existing between SARS-CoV-2 and 
RaTG13 suggested no variant that caused the outbreak 
in humans by the latter. Almost half of the genome 
of the distinct lineage of SARS-CoV is within the 
betacoronavirus and this gives evidence that this novel 
coronavirus is not-mosaic [36]. 
The two important features of the protein spikes are 
the receptor-binding domain (RBD) and the cleavage 
site. RBD can be viewed as a male since it has a kind 
of grapping hook that grips onto the host cells and the 
cleavage site can be seen as a female with a molecular 
can opener that allows the virus to crack open and enter 
host cells. If someone was going to engineer a new 
virus as a pathogen, then the backbone or the molecular 
structure would be a known virus that can cause illness. 
However this virus has mutations in its RBD portion of 
the spike protein and a distinct molecular structure thus, 
this is enough to rule out laboroatory manipulations as a 
potential origin. 
Although the quest to know the exact origin of this 
virus is ongoing and independent research groups were 
able to correlate results of SARS-CoV-2 β-coronavirus, 
with similar geneticmake up to bat coronavirus (Bat-
SARSr-CoV RaTG13). The genome sequence of SARS-
CoV-2 is 96.2% identical to a bat CoV RaTG13, whereas 
it shares 79.5% identity to SARS-CoV. The natural 
source of the virus orgin is suspected to be bat based on 
virus genome sequencing and SARS-CoV-2 might be 
transmitted from bats via unknown intermediate hosts 
to infect humans. The similarities found is the receptor, 
angiotensin-converting enzyme 2 (ACE2) is the same 
for SARS-CoV and they both dpread through respiratory 
mechanisms[11]. 
11. Mutations Occurring within SARS-CoV-2
A study conducted on the genetoype of SARS-CoV-2 
in different patients in different provinces found that, 
the virus had mutated in different patients in China [37]. 
Another study on population genetic analysis of 103 
SARS-CoV-2 genomes revealed two types; SARS-CoV-2 
type L (~ 70%) and S type (~ 30%). The evolutionary 
more aggressive and contagious strains in L types are 
derived from S type [15]. The mutation occurring in the 
NSP2 and NSP3 confers the infectious capability and also 
differentiation mechanism of SARS-CoV-2. This form 
of mutation is crucial for therapeutic targets. However, 
the mutation in S1 spike protein is not affected in the 
sequences and hence the antigen that scientists are 
targeting for vaccine production is not affected. Most 
coronaviruses caused upper respiratory infections like 
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common cold but of recent, fatal respiratory diseases and 
outbreak including the strain that causes COVID-19 has 
the potential to mutate. In fact, the early studies speculate 
that this virus is being caused by mutants from species 
spillover in Wuhan’s wild animal market[38]. However, this 
begs for further studies that will bring in evidence based 
on experiments. 
12. Expectations to See COVID-19 in the Future
With experience from SARS and MERS epidemics, the 
asymptomatic and pre-symptomatic transmission and 
the chances of gene viral mutations, if effective vaccines 
are not develop to win the battle, we are likely to face 
this outbreak again and perhaps in a different form or 
strain. Those receiving antiviral drugs should establish 
a complete elimination of the viral particles in the body. 
Failure for complete eradication will promote drug 
resistance that will lead to drawing back of therapeutic 
interventions back to the basics.
13. Conclusion 
The global citizens must be reminded that in as much as 
we have suffered losses, pain and undending anxieties, 
one fundamental thing that should always be remembered 
is that, an outbreak of disease just like floods, storms and 
earthquakes as well are natural disasters. In essence, there 
should be no stigmamatization or discrimination. We 
need to come clean and plain at the right time for global 
scientific interventions. Both the medical institutions and 
the Governments should be honest and transparent so 
that we can win this war against the novel coronavirus 
by providing the right directions. WHO 2020 continues 
to advise on the importance of solidarity when it comes 
to fighting a common enemy and in containing any 
outbreaks, epidemics or pandemics, discilpine is key as to 
experts guidelines. 
Everyone is affected either directly or indirectly even 
if you are not infected, the outbreak halted the global 
functions and everyone should strive to ensure that bad 
memories are never repeated. Esentially, we need to draw 
our resolution and work towards any similar enemy to 
the human race. It is a collective responsibility to fight 
against this virus in order to stop further spreading by 
providing the right information to the public. If we do not 
come together to fight to win the battle, we might not be 
lucky by be witnessing many countries with long-lasting 
sequela. 
Declarations




Availability of data and material
Not applicable 
Competing interests
The authors declare no competing interests. 
Funding
The publication fee will be reimbursed by Central 
South University, China 
Authors’ contributions




[1] Lisa E. GralinskiandVineet D. Menachery. Return of 
the Coronavirus: 2019-nCoV. Viruses, 2020, 12: 135.
[2] World Health Organization. WHO issues best prac-
tices for naming new human infectious diseases. Up-
dated 2020. Accessed January 29, 2020:
 https://www.who.int/mediacentre/news/notes/2015/
naming-new-diseases/. 
[3] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H .Genomic 
characterisation and epidemiology of 2019 novel 
coronavirus: implications for virus origins and recep-
tor binding. Lancet, 2020, 395(10224): 565-574.
[4] Beavogui, A. H., Delamou, A., Yansane. Clinical 
research during the Ebola virus disease outbreak in 
Guinea: Lessons learned and ways forward. Clinical 
Trials, 2016, 13(1): 73-8. 
[5] Martínez, M. J., Salim, A. M., Hurtado, J. C., Kilgo-
re, P. E. Ebola Virus Infection: Overview and Update 
on Prevention and Treatment. Infect Dis Ther., 2015, 
4(4): 365-90. 
[6] Stremlau, M. H., Andersen, K. G., Folarin, O. A. 
Discovery of Novel Rhabdoviruses in the Blood of 
Healthy Individuals from West Africa. PLoS Neglect-
ed Tropical Diseases, 2015, 9(3). 
[7] Kyei, N. N. A., Abilba, M. M. Imported Lassa fever: 
A report of 2 cases in Ghana. BMC Infectious Dis-
eases, 2015, 15(1). 
[8] Zhou Peng, Yang Xing-Lou. A pneumonia outbreak 
associated with a new coronavirus of probable bat 
origin. Nature, 2020, 579(7798): 270-273
[9] Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H. Composi-
tion and divergence of coronavirus spike proteins and 
host ACE2 receptors predict potential intermediate 
hosts of SARS-CoV-2. J Med Virol., 2020. 
 DOI: 10.1002/jmv.25726
[10] Yin Y, Wunderink RG. MERS, SARS and other 
DOI: https://doi.org/10.30564/jor.v2i2.2447
22
Journal of Oncology Research | Volume 02 | Issue 02 | July 2020
Distributed under creative commons license 4.0
coronaviruses as causes of pneumonia. Respirology, 
2018, 23(2): 130-137.
[11] Meo SA, Alhowikan AM. Novel coronavirus 2019-
nCoV: prevalence, biological and clinical character-
istics comparison with SARS-CoV and MERS-CoV. 
Eur Rev Med Pharmacol Sci., 2020, 24(4): 2012-
2019.
[12] Jia HP, Look DC, Shi L, Hickey M, Pewe L, Net-
land J. ACE2 receptor expression and severe acute 
respiratory syndrome coronavirus infection depend 
on differentiation of human airway epithelia. J Virol., 
2005, 79(23): 14614-21.
[13] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor 
recognition by novel coronavirus from Wuhan: an 
analysis based on decade-long structural studies of 
SARS. J Virol., 2020. 
 DOI: 10.1128/JVI.00127-20
[14] Hofmann, H., Hattermann, K., Marzi, A., Gramberg, 
T., Geier, M., Krumbiegel, M., Kuate, S., Uberla, K., 
Niedrig, M., Pohlmann, S. S protein of severe acute 
respiratory syndrome‐associated coronavirus medi-
ates entry into hepatoma cell lines and is targeted by 
neutralizing antibodies in infected patients. J. Virol., 
2004, 78: 6134-6142. (In English).
[15] Simmons, G., Reeves, J.D., Rennekamp, A.J., Am-
berg, S.M., Piefer, A.J., Bates, P. Characterization 
of severe acute respiratory syndrome‐associated 
coronavirus (SARS‐CoV) spike glycoprotein‐me-
diated viral entry. Proc. Natl. Acad. Sci., USA, 2004, 
101: 4240-4245. (In English).
[16] He, Y., Li, J., Du, L., Yan, X., Hu, G., Zhou, Y., Jiang, 
S. Identification and characterization of novel neu-
tralizing epitopes in the receptor‐binding domain 
of SARS‐CoV spike protein: Revealing the critical 
antigenic determinants in inactivated SARS‐CoV 
vaccine. Vaccine, 2006, 24: 5498-5508. (In English).
[17] Fehr AR, Perlman S. Coronaviruses: an overview of 
the irreplication and pathogenesis. Methods MolBi-
ol., 2015, 1282: 1-23. 
[18] Fung TS, Liu DX. Coronavirus infection, ER stress, 
apoptosis and innate immunity. Front Microbiol., 
2014, 5: 296.
[19] Wu Z, McGoogan JM. Characteristics of and Im-
portant Lessons From the Coronavirus Disease 
2019 (COVID-19) Outbreak in China: Summary of 
a Report of 72 314 Cases From the Chinese Center 
for Disease Control and Prevention. JAMA, 2020, 
323(13): 1239-1242. 
[20] Tonnesen P, Marott JL, Nordestgaard B, Bojesen 
SE, Lange P. Secular trends in smoking in relation 
to prevalent and incident smoking-related disease: A 
prospective population-based study. TobInduc Dis., 
2019, 17. 
[21] Park JE, Jung S, Kim A. MERS transmission and risk 
factors: a systematic review. BMC Public Health, 
2018, 18(1): 574. 
[22] Arcavi L, Benowitz NL. Cigarette smoking and in-
fection. Arch Intern Med., 2004, 164(20): 2206-2216. 
[23] Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 
Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. The Lancet, 2020.
[24] Dong Y, Mo X, Hu Y, Xi Mo, Yabin Hu, Xin Qi, Fan 
Jian. Epidemiological characteristics of 2143 pediat-
ric patients with 2019 coronavirus disease in China. 
Pediatrics. 2020, e20200702.
[25] Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu 
B. Molecular and serological investigation of 2019-
nCoV infected patients: implication of multiple shed-
ding routes. Emerg Microbes Infect, 2020, 9(1): 386-
389.
[26] Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East 
respiratory syndrome coronavirus disease is rare in 
children: an update from Saudi Arabia. World JClin 
Pediatr, 2016, 5: 391-96.
[27] Denison MR. Severe acute respiratory syndrome 
coronavirus pathogenesis, disease and vaccines: an 
update. Pediatr Infect Dis J, 2004, 23: S207-14. 
[28] Hong L, Luo Y. Respiratory viral infections in in-
fants: causes, clinical symptoms, virology, and im-
munology. Clin Microbiol Rev., 2010, 23: 74-98.
[29] Mahmoudjafari Z, Alexander M, Roddy J, Shaw R, 
Shigle TL, Timlin C, Culos K. American Society for 
Transplantation and Cellular Therapy Pharmacy Spe-
cial Interest Group Position Statement on Pharmacy 
Practice Management and Clinical Management for 
COVID-19 in Hematopoietic Cell Transplantation 
and Cellular Therapy Patients in the United States. 
Biol Blood Marrow Transplant, 2020, pii: S1083-
8791(20)30214-7. [Epub ahead of print] Review.
[30] Zhao J, Yuan Q, Wang H. Antibody responses to 
SARS-CoV-2 in patients of novel coronavirus dis-
ease 2019. Clin Infect Dis., 2020. pii: ciaa344.
[31] F u  Y,  C h e n g  Y,  W u  Y.  U n d e r s t a n d i n g 
SARS-CoV-2-Mediated Inflammatory Responses: 
From Mechanisms to Potential Therapeutic Tools.
Virol Sin., 2020. 
 DOI: 10.1007/s12250-020-00207-4 [Epub ahead of 
print]
[32] CDC 2019. Information about Coronavirus Disease 




[33] Chen Y, Peng H, Wang L, Zhao Y, Zeng L, Gao H, 
DOI: https://doi.org/10.30564/jor.v2i2.2447
23
Journal of Oncology Research | Volume 02 | Issue 02 | July 2020
Distributed under creative commons license 4.0
Liu Y. Infants Born to Mothers With a New Corona-
virus (COVID-19). Front. Pediatr., 2020, 8: 104.
[34] Chen H, Guo J, Wang C. Clinical characteristics 
and intrauterine vertical transmission potential of 
COVID‐19 infection in nine pregnant women: a 
retrospective review of medical records. Lancet., 
2020(20): 30360-3.
[35] Zeng L, Xia S, Yuan W. Neonatal Early-Onset In-
fection With SARS-CoV-2 in 33 Neonates Born to 
Mothers With COVID-19 in Wuhan, China. JAMA 
Pediatr. Published online March 26, 2020. 
[36] D. ParaskevisaK E.G, Kostaki. Full-genome evo-
lutionary analysis of the novel corona virus (2019-
nCoV) rejects the hypothesis of emergence as a result 
of a recent recombination event. Infection, Genetics 
and Evolution, 2020, 79: 104212.
[37] Tang X, Wu C, Li X, Song Y, Yao X, Wu X. On the 
origin and continuing evolution of SARS-CoV-2. 
Natl Sci Rev., 2020. 
 DOI: 10.1093/nsr/nwaa036
[38] Jin-Hong Yoo. The Fight against the 2019-nCoV 
Outbreak: an Arduous March Has Just Begun. J Ko-
rean Med Sci., 2020, 35(4): e56.
DOI: https://doi.org/10.30564/jor.v2i2.2447
